Eli Lilly has anted up for its next big bet on a next-gen pain drug, buying Hydra assets

With its new CGRP migraine drug Emgality (galcanezumab) OK’d a few months ago and more late-stage work underway on lasmiditan and tanezumab, Eli Lilly’s pain group has selected its next shot at a next-gen drug.